Specific drug delivery to the kidney

Cardiovascular Drugs and Therapy

Volumn 16, Issue 6, 2002, Pages 489-496

  Haas, Marijke ^a,b   Moolenaar, Frits ^a   Meijer, Dirk K F ^a   De Zeeuw, Dick ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Biomade Technology Foundation   (Netherlands)

Author keywords

ACE inhibitor; Captopril; Kidney; Low molecular weight proteins (LMWP); Naproxen; NSAID; Proximal tubular cell; Targeting

Indexed keywords

CAPTOPRIL; LOW MOLECULAR WEIGHT PROTEIN; LYSOZYME; NAPROXEN; PRODRUG; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG RESEARCH; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVE SITE; FIBROBLAST; GLOMERULUS; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; MESANGIUM CELL; PRIORITY JOURNAL;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY; KIDNEY DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 0242668404     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022913709849     Document Type: Conference Paper

References (55)

1. Kitamura M, Fine LG. The concept of glomerular self-defense. Kidney Int 1999;55:1639-1671.
2. Burton CJ, Walls J. Proximal tubular cell, proteinuria and tubulo-interstitial scarring. Nephron 1994;68:287-293.
3. Johnson RJ. Cytokines, growth factors and renal injury: Where do we go now? Kidney Int Suppl 1997;63:S2-S6.
4. Manil L, Davin JC, Duchenne C, et al. Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro. Pharm Res 1994;11:1160-1165.
5. Kitamura M, Taylor S, Unwin R, Burton S, Shimizu F, Fine LG. Gene transfer into the rat renal glomerulus via a mesangial cell vector: Site-specific delivery, in situ amplification, and sustained expression of an exogenous gene in vivo. J Clin Invest 1994;94:497-505.
6. Pritchard JB, Miller DS. Comparative insights into the mechanisms of renal organic anion and cation secretion. Am J Physiol 1991;261:R1329-R1340.
7. Hoffman BB, Ziyadeh FN. Facilitative glucose transport proteins and sodium-glucose co-transporters in the kidney. Curr Opin Nephrol Hypertens 1995;4:406-411.
8. Murer H. Renal transport of amino acids: Membrane mechanisms. Contrib Nephrol 1982;33:14-28.
9. Christensen EI, Birn H, Verroust P, Moestrup SK. Membrane receptors for endocytosis in the renal proximal tubule. Int Rev Cytol 1998;180:237-284.
10. Leung S, Bendayan R. Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs. Can J Physiol Pharmacol 1999;77:625-630.
11. Moolenaar F, Cancrinius S, Visser J, de Zeeuw D, Meijer DKF. Clearance of indometacin occurs predominantly by renal glucuronidation. Pharm Weekbl [Sci] 1992;14:191-195.
12. Pacifici GM, Viani A, Franchi M, et al. Profile of drug-metabolizing enzymes in the cortex and medulla of the human kidney. Pharmacology 1989;39:299-308.
13. Haga HJ. Kidney lysosomes. Int J Biochem 1989;21:343-345.
14. Suzuki K, Susaki H, Okuno S, Yamada H, Watanabe HK, Sugiyama Y. Specific renal delivery of sugar-modified low-molecular-weight peptides. J Pharmacol Exp Ther 1999;288:888-897.
15. Suzuki K, Susaki H, Okuno S, Sugiyama Y. Renal drug targeting using a vector "alkylglycoside". J Pharmacol Exp Ther 1999;288:57-64.
16. Suzuki K, Ando T, Susaki H, Mimori K, Nakabayashi S, Sugiyama Y. Structural requirements for alkylglycoside-type renal targeting vector. Pharm Res 1999;16:1026-1034.
17. Suzuki K, Susaki H, Okuno S, Yamada H, Watanabe HK, Sugiyama Y. Specific renal delivery of sugar-modified low-molecular-weight peptides. J Pharmacol Exp Ther 1999;288:888-897.
18. Lee MR. Five years' experience with gamma-L-glutamyl-L-dopa: A relatively renally specific dopaminergic prodrug in man. J Auton Pharmacol 1990;10:s103-s108.
19. Orlowski M, Mizoguchi H, Wilk S. N-acyl-gamma-glutamyl derivatives of sulfamethoxazole as models of kidney-selective prodrugs. J Pharmacol Exp Ther 1980;212:167-172.
20. Drieman JC, Thijssen HH, Struyker-Boudier HA. Renal selective N-acetyl-gamma-glutamyl prodrugs. II. Carriermediated transport and intracellular conversion as determinants in the renal selectivity of N-acetyl-gamma-glutamyl sulfamethoxazole. J Pharmacol Exp Ther 1990;252:1255-1260.
21. Barthelmebs M, Caillette A, Ehrhardt JD, Velly J, Imbs JL. Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the isolated rat kidney. Kidney Int 1990;37:1414-1422.
22. Drieman JC, van Kan FJ, Thijssen HH, van Essen H, Smits JF, Struyker-Boudier HA. Regional haemodynamic effects of dopamine and its prodrugs L-dopa and gludopa in the rat and in the glycerol-treated rat as a model for acute renal failure. Br J Pharmacol 1994;111:1117-1122.
23. Minard FN, Grant DS, Cain JC, Jones PH, Kyncl J. Metabolism of gamma-glutamyl dopamide and its carboxylic acid esters. Biochem Pharmacol 1980;29:69-75.
24. Drieman JC, Thijssen HH. Renal selective N-acetyl-L-gamma-glutamyl prodrugs. III. N-acetyl-L-gamma-glutamyl-4′-aminowarfarin is not targeted to the kidney but is selectively excreted into the bile. J Pharmacol Exp Ther 1991;259:766-771.
25. Drieman JC, Thijssen HH, Zeegers HH, Smits JF, Struyker-Boudier HA. Renal selective N-acetyl-gamma-glutamyl prodrugs: A study on the mechanism of activation of the renal vasodilator prodrug CGP 22979. Br J Pharmacol 1990;99:15-20.
26. Casagrande C, Merlo L, Ferrini R, Miragoli G, Semeraro C. Cardiovascular and renal action of dopaminergic prodrugs. J Cardiovasc Pharmacol 1989;14:S40-S59.
27. Elfarra AA, Hwang IY. Targeting of 6-mercaptopurine to the kidneys. Metabolism and kidney-selectivity of S-(6-purinyl)-L-cysteine analogs in rats. Drug Metab Dispos 1993;21:841-845.
28. Franssen EJF, Koiter J, Kuipers CAM, et al. Low-molecular-weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates. J Med Chem 1992;35:1246-1259.
29. Kok R J, Ásgeirsdóttir SA, Verweij WR. Development of proteinaceous drug targeting constructs using chemical and recombinant approaches. In: Molema G, Meijer DKF, eds. Organ specific drug Targ Strategies. Germany: Wiley-VCH, Weinheim, 2001.
30. Haas M, De Zeeuw D, van Zanten A, Meijer DKF. Quantification of renal low-molecular-weight protein handling in the intact rat. Kidney Int 1993;43:949-954.
31. Kau ST, Maack T. Transport and catabolism of parathyroid hormone in isolated rat kidney. Am J Physiol 1977;233:F445-F454.
32. Wallace AL, Stacy BD, Thorburn GD. The fate of radioiodinated sheep-growth hormone in intact and nephrectomized sheep. Pflugers Arch 1972;331:25-37.
33. Bianchi C, Donadio C, Tramonti G, et al. Renal handling of cationic and anionic small proteins: Experiments in intact rats. Contrib Nephrol 1988;68:37-44.
34. Hysing J, Tolleshaug H, Curthoys NP. Reabsorption and intracellular transport of cytochrome c and lysozyme in rat kidney. Acta Physiol Scand 1990;140:419-427.
35. Maack T, Park CH, Camargo MJF. Renal filtration, trans-port, and metabolism of proteins. In: Seldin DW, Giebisch G, eds. The Kidney, Physiology and Pathophysiology. New York: Raven Press, 1985:1773-1803.
36. Christensen EI, Nielsen S. Structural and functional features of protein handling in the kidney proximal tubule. Semin Nephrol 1991;11:414-439.
37. Haas M, De Zeeuw D, Meijer DKF. Quantification of renal low-molecular-weight protein degradation in the intact rat. Contrib Nephrol 1993;101:78-84.
38. Bianchi C, Donadio C, Tramonti G, et al. High and preferential accumulation in the kidney of anionic and cationic small proteins. Contrib Nephrol 1990;83:39-46.
39. Cui S, Verroust PJ, Moestrup SK, Christensen EI. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996;271:F900-F907.
40. Cojocel C, Franzen-Sieveking M, Berndt W, Baumann K. Dependence of renal protein reabsorption on glomerular filtration rate and infusion time. Pflugers Arch 1984;402:34-38.
41. Thielemans N, Lauwerys R, Bernard A. Competition between albumin and low-molecular-weight proteins for renal tubular uptake in experimental nephropathies. Nephron 1994;66:453-458.
42. mTc and urinary ammonia: Effects of proteinuria. Miner Electrolyte Metab 1992;18:108-112.
43. Eisenberger U, Fels LM, Olbricht CJ, Stolte H. Cathepsin B and L in isolated proximal tubular segments during acute and chronic proteinuria. Renal Physiol Biochem 1995;18:89-96.
44. Haas M, De Boer E, Moolenaar F, et al. Renal handling of neutral and cationic low-molecular-weight proteins during proteinuria (abstract). J Am Soc Nephrol 1997;8:A2877.
45. Veronese FM, Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco 1999;54:497-516.
46. Vriesendorp R, Donker AJ, De Zeeuw D, De Jong PE, van der Hem GK, Brentjens JR. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med 1986; 81:84-94.
47. Usberti M, Pecoraro C, Federico S, et al. Mechanism of action of indomethacin in tubular defects. Pediatrics 1985;75:501-507.
48. Franssen EJF, van Amsterdam RGM, Visser J, Moolenaar F, De Zeeuw D, Meijer DKF. Low-molecular-weight proteins as carriers for renal drug targeting: Naproxen-lysozyme. Pharm Res 1991;8:1223-1230.
49. Haas M, Kluppel CA, Wartna ES, et al. Drug-targeting to the kidney: Renal delivery and degradation of a naproxenlysozyme conjugate in vivo. Kidney Int 1997;52:1693-1699.
50. Haas M, Moolenaar F, Meijer DKF, De Jong PE, De Zeeuw D. Renal targeting of a non-steroidal anti-inflammatory drug: Effects on renal prostaglandin synthesis in the rat. Clin Sci 1998;95:603-609.
51. Kok RJ, Grijpstra F, Walthuis RB, Moolenaar F, De Zeeuw D, Meijer DKF. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme. J Pharmacol Exp Ther 1999;288:281-285.
52. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-689.
53. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramiprih The HOPE randomized trial. Ann Intern Med 2001;134:629-636.
54. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-210.
55. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-2219.